BioCryst Pharmaceuticals
BCRX
136 hedge funds and large institutions have $473M invested in BioCryst Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 55 increasing their positions, 24 reducing their positions, and 18 closing their positions.
223% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $570K
129% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 24
117% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 18
67% more capital invested
Capital invested by funds: $283M → $473M (+$190M)
18% more funds holding
Funds holding: 115 → 136 (+21)
0.31% less ownership
Funds ownership: 89.41% → 89.1% (-0.31%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.9M |
| 2 |
EP
Eversept Partners
New York
|
+$10.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.1M |
| 4 |
DM
Deerfield Management
New York
|
+$9.06M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
-$8.24M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$8.14M |
| 3 |
VMI
VHCP Management III
New York
|
-$7.76M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$4.48M |
| 5 |
Morgan Stanley
New York
|
-$1.86M |
BCRX Hedge Fund Activity: Q4 2019 in Review
136 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2019, worth a combined $473M — up 67% from $283M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new BCRX positions and 18 closed out — a net gain of 21 holders — while 55 added to existing stakes and 24 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $12.9M. The largest seller was VHCP Management II, exiting entirely with an estimated $8.24M sold.
- 136 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2019, up from 115 in Q3 2019.
- Funds reported $473M of BioCryst Pharmaceuticals stock for Q4 2019, up 67% quarter-over-quarter.
- 39 funds opened new BioCryst Pharmaceuticals positions in Q4 2019 and 18 closed out, a net change of +21 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2019 was Point72 Asset Management, an estimated $12.9M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2019 was VHCP Management II, an estimated $8.24M sold.
Based on aggregated 13F filings for Q4 2019.